Opko Health (OPK) Drops on Disappointing Trials

Opko Health Inc. (NASDAQ: OPK) shares slipped 1.5% to $9.16, as the company reported disappointing results to a clinical trial. In a press release, Opko Health announced data analysis from a Phase 3 trial which evaluated its long-acting human growth hormone product (hGH-CTP) in adults with growth hormone deficiency (GHD). Share volume was 3.9 million, compared to an all-day average of 4.2 million